CLSA has retained a buy on Apollo Hospitals although it has cut the target price of the stock from Rs 1480 to Rs 1400. The firm expects Apollo Hospitals recovery in business from H2 FY18 onwards.
Lankesh, 55, was an outspoken critic of right-wing extremism.
The S&P BSE Sensex rose a little over 18 percent so far in the year 2017 and history suggest that correction in Indian market were largely a result of some global factors.
Global broking firm CLSA has a sell on Colgate with a target price of Rs 1000 and Credit Suisse is neutral on the stock while Nomura has a buy and has kept a target of Rs 1260.
Citi has retained a buy on Oberoi Realty with a target price of Rs 470 while CLSA has also maintained a buy on the stock with a target of Rs 484 despite impact from GST and RERA.
ITC which holds a weightage of 7.2 percent in Sensex was the biggest contributor for the declines in the index.
The committee will discuss biosimilarity of the product and label extrapolation application by Mylan/Biocon given that they have conducted clinical trials on only one of the three indications, said CLSA.
Post interest payments of Rs 59 billion, the company’s free cash flow turned negative in FY17 from a positive free cash flow of Rs 77 billion in FY16.
CLSA remains positive on Titan and upgrades rating from outperform to BUY and lift our target price from Rs555 to Rs 620 (45x March 2019)
Lemon Tree is backed by Warburg Pincus and the IPO will provide the company an opportunity to encash its investments. The private equity giant holds 20-25% stake in the company. Lemon Tree and Warburg didn’t respond to Moneycontrol’s queries. The IPO may comprise stake sale by promoters as well as issue of fresh shares.
Brokerage house CLSA has downgraded Sun Pharma to sell and has cut the target price from Rs 860 to Rs 500 on the back of 25 percent dip in US sales.
Global investment bank CLSA has maintained a buy rating on ICICI Bank with a revised target price of Rs 380 from Rs 350. The retail segment delivered a 38 percent rise in profit aided by healthy growth in loans, Casa and fees.
Global investment bank, CLSA in a report earlier this week raised 12-month target price to Rs8,100 on expectations of higher demand environment, and volume growth. It raised its 12-month target price to Rs8100 from Rs7600 earlier.
Cipla Q4 net loss narrowed to Rs61.79 crore but muted EBITDA margins led to a downgrade by CLSA to underperform from outperform earlier.
Amid regulatory headwinds from the USFDA and pricing pressure back in India, Jhunjhunwala asked about growing consolidation on the buying side in the industry and can it also extend towards sell side consolidation.
The pharma major reported 49.2 percent YoY decline in the net profit to Rs 380.2 crore in the fourth quarter ended March on account of drop in US sales and a one-time provisioning
Ace investor Rakesh Jhunjhunwala of RARE Enterprises who holds close to 9 percent stake in Titan Company along with his wife Rekha Jhunjhunwala expressed his concerns about flat margin as well as the poor payout ratio.
The telecom major registered a sharp 72 percent decline in consolidated net profit at Rs 373.4 crore for the fourth quarter ended March 2017.
Government's focus on affordable housing and RERA are the two big drivers for the real estate space but the overall affordability is also close to its all-time best in two decades, said Mahesh Nandurkar, India Strategist, CLSA.
In December quarter, revenues of nine telecom operator declines by 1.1 percent, according to CARE Ratings. The operating margin for the industry stood at 28.43 percent.
AB Fashion, Voltas and Welspun India are among a few stocks that investors are focusing on Monday.
CLSA believes FII flows should remain conducive as India's relative performance has also improved.
Credit Suisse maintains an outperform rating on United Spirits with a 12-month target price of Rs 2,500.
Bharat Financial Inclusion, Airtel and Zee Entertainment could be on investors' mind. Meanwhile, they also have a view on information technology and automobile sector.